Tenaya Therapeutics, Inc. (TNYA) Stock Forecast
TNYA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 6 analysts
- Price target
- $3.20 average of analyst targets
- Upside to target
- +740.6% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.10
- 52-week range
- $0.38 – $1.97
TNYA analyst ratings
6 analystsNumber of analysts at each rating.
TNYA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TNYA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | −$0.10 | −$0.09 | −$0.12 | +20.8% | 4 |
| Current fiscal year (2026) | −$0.42 | −$0.49 | −$0.36 | −$0.59 | +29.4% | 3 |
| Next fiscal year (2027) | −$0.39 | −$0.47 | −$0.35 | −$0.42 | +5.9% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TNYA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $800,000 | $0 | $1.1M | 0.0% | 4 |
| Current fiscal year (2026) | $4.0M | $1.3M | $10.2M | 0.0% | 5 |
| Next fiscal year (2027) | $2.5M | $0 | $5.6M | −37.4% | 4 |
TNYA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TNYA revenue: reported and forecast
TNYA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | −$0.10 | −$0.10 | −$0.10 | −$0.10 | −3.7% | 0 up · 3 down |
| Current fiscal year (2026) | −$0.38 | −$0.38 | −$0.46 | −$0.43 | −$0.42 | +8.9% | 0 up · 3 down |
| Next fiscal year (2027) | −$0.41 | −$0.41 | −$0.41 | −$0.41 | −$0.39 | −5.3% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TNYA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TNYA beat in 10 of 12.
What analysts expect from TNYA
6 analysts cover Tenaya Therapeutics; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $3.20, 740.6% above the latest close of $0.38. Analysts expect earnings of −$0.42 per share for 2026, +29.4% from a year earlier. For 2027 the average estimate is −$0.39 per share on revenue of $2.5 million. Tenaya Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: TNYA income statement, TNYA key metrics, TNYA chart. See the TNYA stock overview for the latest quote and news.
TNYA forecast FAQ
What is Tenaya Therapeutics's price target?
The average analyst price target for Tenaya Therapeutics is $3.20, 740.6% above the latest close of $0.38.
Is Tenaya Therapeutics a buy, hold or sell?
Of 6 analysts covering Tenaya Therapeutics, 4 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Tenaya Therapeutics's EPS forecast?
Analysts forecast −$0.42 per share for 2026 (range −$0.49 to −$0.36); for 2027 the estimate is −$0.39.
What is Tenaya Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $4.0 million, growth of 0.0%; for 2027 it is $2.5 million.
When does Tenaya Therapeutics report earnings?
Tenaya Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-0.10.
Does Tenaya Therapeutics usually beat earnings estimates?
Tenaya Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.